New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 855-860

  Umene, Kiyoko ^a   Banno, Kouji ^a   Kisu, Iori ^a   Yanokura, Megumi ^a   Nogami, Yuya ^a   Tsuji, Kosuke ^a   Masuda, Kenta ^a   Ueki, Arisa ^a   Kobayashi, Yusuke ^a   Yamagami, Wataru ^a   Tominaga, Eiichiro ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; Fourth generation progestins; Metformin; MicroRNA; MTOR inhibitors

Indexed keywords

APICIDIN; BUTYRIC ACID; CARBOXYCINNAMIC ACID BISHYDROXAMIDE; CHLAMYDOCIN; DESOGESTREL; DIENOGEST; EVEROLIMUS; GESTAGEN; GONADORELIN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; LEVONORGESTREL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE ACETATE; METFORMIN; MICRORNA; NORETHISTERONE; RIDAFOROLIMUS; TEMSIROLIMUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACNE; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE DENSITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE ARREST; DNA METHYLATION; DRUG STRUCTURE; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; GONADAL DISEASE; HIRSUTISM; HUMAN; HYSTERECTOMY; LIBIDO; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SIDE EFFECT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; METFORMIN; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROGESTINS;

EID: 84872780227     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2221     Document Type: Review

References (37)

1. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T and The Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42: 139-147, 2012.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 41: 139-147, 2011.
3. Amant F, Van Calsteren K, Vergote I and Ottevanger N: Gynecologic oncology in pregnancy. Crit Rev Oncol Hematol 67: 187-195, 2008.
4. Fleming GF, Brunetto VL and Cella D: Phase III trial of doxo-rubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Jpn J Clin Oncol 22: 2159-2166, 2004. (Pubitemid 41095150)
5. Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM and Duska LR: Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31: 979-987, 2007. (Pubitemid 47012293)
6. Hamilton CA, Cheung MK, Osann K, Balzer B, Berman ML and Husain A: The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol 103: 679-683, 2006. (Pubitemid 44602186)
7. Kelly MG, O'Malley DM, Hui P, et al: Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 98: 353-359, 2005. (Pubitemid 41169144)
8. Zanotti KM, Belinson JL, Kennedy AW, Webster KD and Markman M: The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 74: 272-277, 1999. (Pubitemid 29377225)
9. Alexander IF, Shine J and Sutherland RL: Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells. Mol Endocrinol 4: 821-828, 1990.
10. Kashima H, Horiuchi A, Uchikawa J, Miyamoto T, Suzuki A, Ashida T, Konishi I and Shiozawa T: Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma. Anticancer Res 29: 1023-1029, 2009.
11. Miyamoto T, Horiuchi A, Kashima H, Suzuki A, Yamada T, Kurai M, Konishi I and Shiozawa T: Inverse correlation between Skp2 and p27(Kip1) in normal endometrium and endometrial carcinoma. Gynecol Endocrinol 26: 220-229, 2010.
12. Banno K, Kisu I, Yanokura M, et al: Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (Review). Int J Oncol 40: 1755-1762, 2012.
13. Katsuki Y, Shibutani Y, Aoki D and Nozawa S: Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 79: 169-176, 97.
14. Nakamura M, Katsuki Y, Shibutani Y and Oikawa T: Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 386: 33-40, 1999. (Pubitemid 30009620)
15. Katayama H, Katayama T, Uematsu K, Hiratsuka M, Kiyomura M, Shimizu Y, Sugita A and Ito M: Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod 25: 2851-2858, 2010.
16. Gerlinger C, Faustmann T, Hassal JJ and Seitz C: Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials. BMC Womens Health 12: 9, 2012.
17. Foster RH and Wilde MI: Dienogest. Drugs 56: 825-833, 1998.
18. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511, 2009.
19. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.
20. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y and Liao QP: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endo-metrial cancer cells. J Steroid Biochem Mol Biol 126: 113-120, 2010.
21. Tsuji K, Kisu I, Banno K, et al: Metformin: a possible drug for treatment of endometrial cancer. OJOG 2: 1-6, 2012.
22. Bednar F and Simeone DM: Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res 5: 351-354, 2012.
23. Huang S and Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3: 371-377, 2003. (Pubitemid 36908940)
24. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB and Reis-Filho JS: Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261-271, 2011.
25. Oda K, Shoji K, Nakagawa S, et al: Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 29: e37431, 2012.
26. Colombo N, McMeekin S, Schwartz P, et al: A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 25: 5516, 2007.
27. Slomovitz BM, Lu KH, Johnston T, et al: A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116: 5415-5419, 2010.
28. Oza AM, Elit L, Biagi J, et al: Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. J Clin Oncol 24: 3003, 2004.
29. Oza A, Elit L, Provencher D, et al: A phase II study of temsi-rolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 26: 5516, 2008.
30. Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Susumu N and Aoki D: Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics 4: 147-162, 2012.
31. Kawaguchi M, Banno K, Yanokura M, et al: Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int J Oncol 35: 977-982, 2009.
32. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 110: 206-215, 2008.
33. Tsuruta T, Kozaki K, Uesugi A, et al: miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 20: 6450-6462, 2011.
34. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I and Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004. (Pubitemid 38198916)
35. Takai N, Ueda T, Nishida M, Nasu K, Matsuda K, Kusumoto M and Narahara H: CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Oncology 70: 97-105, 2006. (Pubitemid 43760335)
36. Ueda T, Takai N, Nishida M, Nasu K and Narahara H: Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med 19: 301-308, 2007.
37. Kato K, Kuhara A, Yoneda T, et al: Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response. Mol Cancer Ther 10: 1430-1439, 2011.